Pre-therapeutic dosimetry of normal organs and tissues of Lu-177-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer


Kabasakal L., AbuQbeitah M., Aygun A., Yeyin N. , Ocak M. , Demirci E. , ...More

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.42, no.13, pp.1976-1983, 2015 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 42 Issue: 13
  • Publication Date: 2015
  • Doi Number: 10.1007/s00259-015-3125-3
  • Title of Journal : EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • Page Numbers: pp.1976-1983

Abstract

Purpose Lu-177-617-prostate-specific membrane antigen (PSMA) ligand seems to be a promising tracer for radionuclide therapy of progressive prostate cancer. However, there are no published data regarding the radiation dose given to the normal tissues. The aim of the present study was to estimate the pretreatment radiation doses in patients who will undergo radiometabolic therapy using a tracer amount of Lu-177-labeled PSMA ligand.